📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of medicines iii/2026 { "detected_language": "romanian", "translated_text": "lot-0013, title: diprogenta cream ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0014, title: diprogenta ointment ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0018, title: bromazepam lph 1.5 mg or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0040, title: diprosalic ointment ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0041, title: diprophos ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0042, title: biorinil 0.5 mg/1 mg/ml nasal spray ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0056, title: adrenostazin ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0057, title: cefaclor therapy 500 mg, cefaclor arena 500 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0065, title: chlorzoxazone ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0076, title: aspatofort or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0077, title: fragmin 5000 ui ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0082, title: duodart 0.5 mg/0.4 mg or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0108, title: epipen 300 mcg meda pharma ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and estimated value excluding vat: 205905.30 ron.Centralized framework agreement for 24 months for the supply of medicines iii/2026
